Polypoidal choroidal vasculopathy - Pipeline Insight, 2024

Polypoidal choroidal vasculopathy - Pipeline Insight, 2024

DelveInsight’s, “Polypoidal Choroidal Vasculopathy - Pipeline Insight, 2024,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Polypoidal Choroidal Vasculopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Polypoidal Choroidal Vasculopathy Understanding

Polypoidal Choroidal Vasculopathy: Overview

Polypoidal Choroidal Vasculopathy (PCV) is a neovascular AMD which is presented by multiple recurrent serosanguinous maculopathy or bilateral detachment of retinal pigment epithelial (PED). This condition is due to abnormality of inner choroidal vessel and tends to cause polyploidal protrusions. Individuals with cardiovascular abnormalities, diabetes mellitus, obstructive sleep apnoea, and ocular abnormalities such as choroidal thickening are likely to be associated with PCV. PVC is more prevalent among the Asian and African population and largely affects male in comparison to females with a mean age of 61 years. Photodynamic therapy and anti-VEGF agents alone or in combination can be used to treat PVC to some extent.

""Polypoidal Choroidal Vasculopathy - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polypoidal Choroidal Vasculopathy pipeline landscape is provided which includes the disease overview and Polypoidal Choroidal Vasculopathy treatment guidelines. The assessment part of the report embraces, in depth Polypoidal Choroidal Vasculopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polypoidal Choroidal Vasculopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Polypoidal Choroidal Vasculopathy R&D. The therapies under development are focused on novel approaches to treat/improve Polypoidal Choroidal Vasculopathy.

Polypoidal Choroidal Vasculopathy Emerging Drugs Chapters

This segment of the Polypoidal Choroidal Vasculopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Polypoidal Choroidal Vasculopathy Emerging Drugs

• Aflibecept: Bayer AG

Aflibercept is a recombinant fusion protein. It is currently under Phase III development for the treatment of Polypoidal Choroidal Vasculopathy. It is an anti-VEGF molecule that binds to the freely floating VEGF and inhibit the activity of VEGF A and VEGF B as well as placental growth factor.

• Zimura: IVERIC Bio, Inc.

Zimura is a polyethylene glycol that inhibits the cleavage of C5 fragment into C5a and C5b. The molecule is in Phase II of the clinical trial for the treatment of idiopathic Polypoidal Choroidal Vasculopathy.

Further product details are provided in the report……..

Polypoidal Choroidal Vasculopathy: Therapeutic Assessment

This segment of the report provides insights about the different Polypoidal Choroidal Vasculopathy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Polypoidal Choroidal Vasculopathy

There are approx. 4+ key companies which are developing the therapies for Polypoidal Choroidal Vasculopathy. The companies which have their Polypoidal Choroidal Vasculopathy drug candidates in the most advanced stage, i.e. phase III include, Bayer AG.

• Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Polypoidal Choroidal Vasculopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Polypoidal Choroidal Vasculopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polypoidal Choroidal Vasculopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polypoidal Choroidal Vasculopathy drugs.

Polypoidal Choroidal Vasculopathy Report Insights

• Polypoidal Choroidal Vasculopathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Polypoidal Choroidal Vasculopathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Polypoidal Choroidal Vasculopathy drugs?
• How many Polypoidal Choroidal Vasculopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polypoidal Choroidal Vasculopathy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polypoidal Choroidal Vasculopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Polypoidal Choroidal Vasculopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bayer AG
• IVERIC bio, Inc.
• Novartis

Key Products

• Aflibecept
• Zimura
• Ranibizumab